It has only been a few short years since GLP-1 drugs exploded in popularity, yet their impact on the healthcare landscape is undeniable. In fact, the market for these drugs is projected to grow from an estimated $46.7 billion in 2024 to $471 billion by 2032.
The GLP-1 trend shows no signs of slowing down, which is why we devoted our latest episode of Pharmland [insert link] to help understand what to expect from the GLP-1 market in 2026. 
The forces driving unprecedented demand
GLP-1 drugs have captured the public’s attention like few medications before them. Originally intended for managing blood sugar in adults with Type 2 diabetes, their effectiveness in obesity-related weight loss significantly broadened their appeal. In addition, different GLP-1s have also gone on to obtain expanded indications to treat certain cardiovascular conditions, chronic kidney disease risks, and even sleep apnea.
This, combined with direct-to-consumer advertising, celebrity endorsements, and powerful social media trends, has created a powerful driver for demand that directly impacts employer-sponsored health plans.
In fact, reports show that as many as 12% of the U.S. population has tried a GLP-1 medication. That’s why managing GLP-1s’ impact on the bottom line requires a proactive strategy.
What’s next for GLP-1s?
While almost all plan sponsors have witnessed the cost impact of these drugs to some degree, what many may not realize is that the GLP-1 story is just beginning. The pipeline is filled with new developments that will likely increase their use and market impact for years to come.
Expanded indications: Researchers are studying GLP-1 therapies for a wide range of conditions beyond diabetes and obesity. These include non-alcoholic fatty liver disease (also known as MASH), psoriasis, and even addiction and neurodegenerative diseases like Alzheimer’s. Each new approval will further widen the patient base.
Combination therapies: Manufacturers are exploring pairing GLP-1s with other drugs to enhance their effectiveness. For example, studies are underway to combine these therapies with anti-inflammatory drugs to treat conditions such as psoriasis, where weight and inflammation are linked. These combinations could lead to more comprehensive treatments for complex diseases.
New mechanisms of action: Manufacturers are continuing to innovate and investigate new pathways and receptors to create even more potent and effective treatments. This drive to differentiate products in a competitive market will continue to push the boundaries of what these drugs can do, thereby protecting their market share.
The high cost of a blockbuster drug class
For employers and benefits advisors, the primary challenge is the steep price tag. A single prescription for a GLP-1 can often exceed $1,000 per month. When you multiply that cost by a growing number of eligible employees, the financial implications become immense.
Without effective management, these costs can quickly strain pharmacy benefits budgets. An RxBenefits analysis found that without proper clinical oversight, up to 40% of GLP-1 prescriptions could be for uses not covered by a plan. Employers must find a way to balance providing access to these effective treatments with maintaining control over their healthcare spending. This requires a thoughtful approach to plan design and utilization management.
GLP-1s will remain a dominant force in pharmacy benefits in 2026. By staying informed and agile, employers and their benefits advisors can navigate this complex landscape, manage costs effectively, and support the health of their employees. Watch this space for an upcoming blog post about the strategies employers can take to manage the GLP-1 trend.
In the meantime, check out our latest Pharmland podcast to learn more.
